Is it worth treating Category I failure patients with Category II regimen.
dc.contributor.author | Santha, T | |
dc.contributor.author | Gopi, P G | |
dc.contributor.author | Rajeswari, R | |
dc.contributor.author | Selvakumar, N | |
dc.contributor.author | Subramani, R | |
dc.contributor.author | Chandrasekaran, V | |
dc.contributor.author | Rani, B | |
dc.contributor.author | Thomas, A | |
dc.contributor.author | Narayanan, P R | |
dc.date.accessioned | 2013-05-29T06:38:25Z | |
dc.date.available | 2013-05-29T06:38:25Z | |
dc.date.issued | 2005-10 | |
dc.description.abstract | Background: Very little information is available on the drug susceptibility profile among patients who are treated with standardized short-course chemotherapy regimens under programme conditions. Methods: Sputum samples were collected from new sputum smear-positive patients declared ‘failure’ after treatment with Category I regimen under tuberculosis control programme using DOTS strategy from a rural area of Tamil Nadu. Results: Of 1463 patients started on Category I regimen between May1999 and December 2002, 74 cases were declared as ‘failures’ (smear positive at 5/6 months of treatment). We collected sputum samples from 60 (81%) of 74 ‘failures’ and 27% (16 of 60) of them were culture-negative for M tuberculosis and 17% (10 of 60) had organisms resistant to Isoniazid and Rifampicin (MDR TB). Conclusion: Based on the drug susceptibility profile at the time of ‘failure’, treating Category I ‘failures’ with Category II regimen with close monitoring appears to be justified. | en_US |
dc.identifier.citation | Santha T, Gopi P G, Rajeswari R, Selvakumar N, Subramani R, Chandrasekaran V, Rani B, Thomas A, Narayanan P R. Is it worth treating Category I failure patients with Category II regimen. Indian Journal of Tuberculosis. 2005 Oct; 52(4): 203-206. | en_US |
dc.identifier.uri | https://imsear.searo.who.int/handle/123456789/146975 | |
dc.language.iso | en | en_US |
dc.source.uri | https://medind.nic.in/ibr/t05/i4/ibrt05i4p203.pdf | en_US |
dc.subject | Tuberculosis | en_US |
dc.subject | DOTS | en_US |
dc.title | Is it worth treating Category I failure patients with Category II regimen. | en_US |
dc.type | Article | en_US |